Youbin Zhang

Youbin Zhang

Auto-generated profile, based on publicly available information

Youbin Zhang

Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 1

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NDNurmaa K. Dashzeveg
Nurmaa K. Dashzeveg
YJYuzhi Jia
Yuzhi Jia
YZYoubin Zhang
Youbin Zhang
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
PPPriyam Patel
Priyam Patel
HLHuiping Liu
Huiping Liu
Most circulating tumor cells (CTC) are detected as single cells, whereas a small proportion of CTCs in multicellular clusters with stemness properties possess 20- to 100-times higher metastatic propensity than the single cells. Here we report that CTC dynamics in both singles and clusters in response to therapies predict overall survival for breast cancer. Chemotherapy-evasive CTC clusters are relatively quiescent with a specific loss of ST6GAL1-catalyzed α2,6-sialylation in glycoproteins. Dynamic hyposialylation in CTCs or deficiency of ST6GAL1 promotes cluster formation for metastatic seeding and enables cellular quiescence to evade paclitaxel treatment in breast cancer. Glycoproteomic analysis reveals newly identified protein substrates of ST6GAL1, such as adhesion or stemness markers PODXL, ICAM1, ECE1, ALCAM1, CD97, and CD44, contributing to CTC clustering (aggregation) and metastatic seeding. As a proof of concept, neutralizing antibodies against one newly identified contributor, PODXL, inhibit CTC cluster formation and lung metastasis associated with paclitaxel treatment for triple-negative breast cancer. Significance: This study discovers that dynamic loss of terminal sialylation in glycoproteins of CTC clusters contributes to the fate of cellular dormancy, advantageous evasion to chemotherapy, and enhanced metastatic seeding. It identifies PODXL as a glycoprotein substrate of ST6GAL1 and a candidate target to counter chemoevasion-associated metastasis of quiescent tumor cells. This article is featured in Selected Articles from This Issue, p. 1949

3 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
QZQiang Zhang
Qiang Zhang
ZCZheng Cai
Zheng Cai
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
ADAndrew Davis
Andrew Davis
PDPaolo D’aMico
Paolo D’aMico
WGWilliam J. Gradishar
William J. Gradishar
Purpose: Early evaluation of tumor heterogeneity related to metastasis and outcomes is a major challenge in the management of advanced breast cancer (BCa) in the clinic. In this study, we introduced the value of baseline circulating tumor cells (CTC) and ctDNA for early differentiation of clinical stages, tumor heterogeneity, and prognosis in clinic. Experimental Design: A total of 292 patients with BCa were enrolled in this study, including 254 Stage IV and 38 Stage III patients, and examined the baseline levels of CTCs, CTC-clusters, and plasma ctDNA before initiating therapies. Outcomes including progression-free survival (PFS) and overall survival were evaluated using proportional hazards regression analysis. Results: The baseline CTCs, including HER2+ CTCs, in Stage IV patients were approximately 9.5 times higher than those detected in Stage III patients. Baseline CTC counts with a cutoff of 5 were significantly associated with the prognosis. Within each stage, patients with <5 CTCs had significantly longer PFS. Stage III patients with no CTCs exhibited the longest survival compared with patients with ≥1 CTC. CTC-clusters were only found in Stage IV patients, among whom 15 Stage IV patients with ≥5 CTC-clusters had the worst PFS compared with the 239 Stage IV patients with <5 CTC-clusters. Similar outcomes were observed in 28 out of 254 Stage IV patients who had at least one CTC-cluster detected, as these patients had shorter PFS compared with CTC-cluster negative group. The major differences in ctDNA mutations between patients with Stage III and Stage IV BCa were in PIK3CA and ESR1, which were associated with specific organ metastasis and worse outcomes. Conclusions: Assessing the baseline levels of CTCs, CTC-clusters, and mutational ctDNA profile could reliably aid in differentiation of clinical stage and early prediction of metastasis and outcomes in advanced BCa.

9 August 2023
Verified
Other
Open access
NDNurmaa K. Dashzeveg
Nurmaa K. Dashzeveg
YJYuzhi Jia
Yuzhi Jia
YZYoubin Zhang
Youbin Zhang
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
PPPriyam Patel
Priyam Patel
HLHuiping Liu
Huiping Liu
Supplementary Video S8 shows the clustering video of scrRNA transfected ST6KO cells presented in Fig.5E.

9 August 2023
Verified
Other
Open access
NDNurmaa K. Dashzeveg
Nurmaa K. Dashzeveg
YJYuzhi Jia
Yuzhi Jia
YZYoubin Zhang
Youbin Zhang
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
PPPriyam Patel
Priyam Patel
HLHuiping Liu
Huiping Liu
Supplementary Video S12 shows the clustering video of siICAM1 transfected ST6KO cells presented in Fig.5E.

9 August 2023
Verified
Other
Open access
NDNurmaa K. Dashzeveg
Nurmaa K. Dashzeveg
YJYuzhi Jia
Yuzhi Jia
YZYoubin Zhang
Youbin Zhang
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
PPPriyam Patel
Priyam Patel
HLHuiping Liu
Huiping Liu
Supplementary Video S6 shows the clustering video of PAX treated cells presented in Fig.2E.

9 August 2023
Verified
Other
Open access
NDNurmaa K. Dashzeveg
Nurmaa K. Dashzeveg
YJYuzhi Jia
Yuzhi Jia
YZYoubin Zhang
Youbin Zhang
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
PPPriyam Patel
Priyam Patel
HLHuiping Liu
Huiping Liu
Supplementary Video S14 shows the clustering video of scrRNA transfected ST6WT cells presented in Fig.5E.